Cytosorbents Corporation Культура компании

Dr. Phillip P. Chan, M.D., Ph.D. has been the Chief Executive Officer of Cytosorbents Corporation since January 2009 and serves as its President. Dr. Chan serves as a Partner of NJTC Venture Fund. He co-founded Andrew Technologies. He led investments in the healthcare, medical device, life sciences and biotechnology sectors and is based at NJTC's Mount Laurel office. He served as an Interim Chief Executive Officer of MedaSorb Technologies Corporation. Dr. Chan has been a Director of MedaSorb Technologies Corporation since July 24, 2008. He serves as a Director of Andrew Technologies. He serves as a Board Observer of Intra-Cellular Therapies, InstaMed, Sword Diagnostics and others. He has been a Director of Cytosorbents Corporation since July 24, 2008. He served as Director of IntegriChain, Inc. He is a Board-certified Internal Medicine Physician and helped pioneer new advances in oligonucleotide-based gene therapy at Yale University School of Medicine. Dr. Chan completed his Internal Medicine residency at the Beth Israel Deaconess Medical Center at Harvard and also received a B.S. degree in Cell and Molecular Biology, with honors and distinction, from the Cornell University. He received an M.D. and a Ph.D. in Genetics from the Yale University School of Medicine.

Ms. Kathleen P. Bloch, also known as Kathy, MBA, CPA, serves as Chief Financial Officer of CytoSorbents Incorporated and Silver Line Building Products, LLC. Ms. Bloch has been the Chief Financial Officer at Cytosorbents Corporation since May 29, 2013 and serves as its Principal Accounting Officer and Secretary. She has more than 20 years of executive financial experience in both public and private companies. Ms. Bloch served as the Chief Financial Officer of Laureate Biopharmaceutical Services, Inc. (Laureate Pharma, Inc). since November 2010. She served as Chief Operating Officer of PC Group, Inc. (Alternatively, Langer Inc). since October 8, 2008 to November 5, 2010. Ms. Bloch served as Chief Financial Officer and Vice President of PC Group, Inc. (Alternatively, Langer Inc.). since September 4, 2007 to November 05, 2010 and served as its Secretary from September 4, 2007 to November 05, 2010. Ms. Bloch served as Chief Financial Officer of Silver Line Building Products Inc. (Silver Line Building Products LLC) from August 1999 to January 2006. In January 2006, she added the title of Chief Operating Officer of Silver Line to her responsibilities and remained in those positions until the sale of Silver Line in late 2006. Following the sale of Silver Line, she served for Silverman Group as the Chief Operating Officer. She started her career as an Auditor at Peat Marwick in Philadelphia. Ms. Bloch graduated from LaSalle University with Bachelor of Science Degree in Accounting in 1978 and received her Master of Business Administration with a concentration in Finance from LaSalle in 1990.

Mr. Vincent J. Capponi, also known as Vince, MS has been the Chief Operating Officer of Cytosorbents Corporation (formerly, known as MedaSorb Technologies, Inc.) is the operating company of MedaSorb Technologies Corporation (www.medasorb.com) since July 2005. Mr. Capponi joined CytoSorbents Inc. as Vice President of Operations in 2002. Mr. Capponi has more than 20 years of management experience in medical device, pharmaceutical and imaging equipment at companies including Upjohn, Sims Deltec and Sabratek. He served as Chief Operating Officer of Gilder Enterprises, Inc. Prior to joining CytoSorbents, he held several senior management positions at Sabratek and its diagnostics division GDS and was interim president of GDS diagnostics in 2001. He served as Senior Vice President and Chief Operating Officer for Sabratek Corporation from 1998 to 2000 and also as its Vice President of Operations from 1996 to 1998. Mr. Capponi served as Vice President of Quality Control of Sabratek Corp. since September 1999. Before joining Sabratek Corp., from 1992 to 1996, he was employed by SIMS Deltec, Inc., formerly Pharmacia Deltec, Inc., a manufacturer and marketer of ambulatory drug delivery and vascular access devices and served as its Director of Operations. From 1984 to 1992, he served in a variety of positions with Mead Imaging, a division of Mead Corporation, which commercialized a new color-imaging technology. He holds an MS in Chemistry and a BS in Chemistry and Microbiology from the Bowling Green State University.

Dr. Christian Steiner, M.D., serves as Vice President of Sales and Marketing at CytoSorbents Incorporated. Dr. Steiner has been a Vice President of Sales and Marketing at Cytosorbents Corporation since June 2012. Dr. Steiner serves as Managing Director of CytoSorbents European sales subsidiary, CytoSorbents Europe GmbH in Berlin, Germany. He manages all direct sales and marketing efforts of CytoSorb in Germany and distributor relationships elsewhere in Europe. Dr. Steiner is instrumental in increasing awareness of CytoSorb amongst key opinion leaders during the controlled market release and helping to establish the necessary selling infrastructure in Europe, including the recruitment of a core veteran sales team in Germany. He has 12 years of experience in introducing new technologies to the intensive care unit, starting with the Molecular Adsorbent Recirculation System, better known as MARS. He has strong customer relationships, combined with medical background and sales and marketing skills. Dr. Steiner served at Critical Care Competence as Managing Director. He served as the Director of Corporate Marketing for Pulsion Medical Systems AG, where he was responsible for launching new products such as PiCCO , establishing physician relationships, building market awareness, initiating clinical studies and helping to grow sales to approximately 30 million. He served as Director of Global Marketing at Teraklin AG, where he led the clinical introduction of MARS. Dr. Steiner has Medical Degree from the University of Rostock, Germany, defending his thesis while graduating Magna Cum Laude and was a Research Fellow at the Institute of Hepatology at University College London.

Dr. Robert H. Bartlett, M.D. served as the Chief Medical Officer at Cytosorbents Corporation (Formerly, MedaSorb Technologies Corporation) since January 2009 until June 1, 2017 and has been its Co-Chairman of U.S. Cardiac Surgery Advisory Board and Consultant since June 1, 2017. Dr. Bartlett is the Co- Founder of MC3 Inc. He is the founder of the Extracorporeal Life Support Organization (ELSO). He serves as Director of MC3 Inc. He serves as the Director of the Cardiopulmonary Physiology and Extracorporeal Circulation Research Laboratory. Dr. Bartlett has wealth of research and clinical experience including management of sepsis, acute respiratory distress syndrome and mechanical life support systems and continues to be active in lab and clinical research. Dr. Bartlett is Professor Emeritus of Surgery at the University of Michigan Health System. Prior to becoming Professor Emeritus in 2005, he served as Director of the Surgical Intensive Care Unit, Chief of the Trauma/Critical Care division and Director of the Extracorporeal Life Support Program at the University of Michigan Medical Center. Dr. Bartlett was the pioneer in the development of the extracorporeal membrane oxygenation machine (ECMO), used to oxygenate blood in critically ill patients worldwide. Dr. Bartlett was a NIH Trainee in Academic Surgery at Harvard Medical School and was previously faculty at the University of California, Irvine. He is the recipient of 26 separate research grants, 14 from the National Institutes of Health, including an RO1 grant for the development of a totally artificial lung. He has also received numerous national and international awards for his contributions to critical care medicine. He completed his general surgery residency at Peter Bent Brigham Hospital in Boston and was Chief resident in thoracic surgery. He received his MD from the University of Michigan Medical School, cum laude.

Dr. Eric G. Mortensen, M.D., Ph.D. has been Chief Medical Officer at Cytosorbents Corporation since June 01, 2017. Dr. Mortensen has been Chief Medical Officer at CytoSorbents Incorporated since June 26, 2017. He has more than 20 years of clinical trial experience. He has led clinical development of key programs for some of the largest pharmaceutical companies in the world, including Pfizer's novel rheumatoid arthritis therapy, Xeljanz??, which has achieved approximately $1 billion in annual worldwide sales. He has more than two decades of proven and successful clinical trial development expertise as well as a wealth of knowledge and experience in immunology, inflammation and clinical medicine. He served as Vice President & Therapeutic Area Clinical Head for Inflammation and Immunology at Pfizer from 2014 to 2016 and led the company's global, late-stage development organization for programs in inflammatory diseases including studies for Enbrel?? and Xeljanz??. As the Clinical Inflammation Development Strategy Lead and co-chair for Inflammation's Therapeutic Area Strategy Team (TAST), he ensured an integrated approach to the development of medicines across the different indications within Inflammation and Immunology. Dr. Mortensen previously held positions of increasing responsibility as the Vice President, Global Medicine Development Group Global Lead for Xeljanz and Assistant Vice President and Global Therapeutic Area Director for Enbrel. Previously at GlaxoSmithKline, he led clinical programs for the reintroduction of alosetron to the US market, the registration program for alvimopan and medical affairs programs for assets within Women's Health, Urology, Acute Care, Gastrointestinal and Ophthalmologic business units. Prior to this, at Merck Research Laboratories, he was responsible for registration studies of the COX2 inhibitors rofecoxib and etoricoxib. Dr. Mortensen received an A.B. in Biochemistry from Harvard College, an M.D. from the Harvard University and Massachusetts Institute of Technology Division of Health Sciences and Technology (HST), and a Ph.D. in Biophysics at the Harvard Graduate School of Arts and Sciences where he studied the transduction of membrane-bound hormone receptor's binding into intracellular activation of metabolic activity and cellular proliferation. Dr. Mortensen completed an internship and residency in Internal Medicine at the Massachusetts General Hospital and a fellowship in Gastroenterology at the University of Michigan Medical Center, Ann Arbor.

Kathleen Bloch serves as the Chief Financial Officer of CytoSorbents Corporation. Kathleen started at CytoSorbents Corporation in May of 2013. Kathleen currently resides in the Greater New York City Area.

Eric Mortensen serves as the Chief Medical Officer of CytoSorbents Corporation. Eric started at CytoSorbents Corporation in May of 2017. Eric currently resides in the Greater New York City Area.

Vincent Capponi serves as the COO of CytoSorbents Corporation. Vincent started at CytoSorbents Corporation in November of 2008. Vincent currently resides in the Greater New York City Area.

Chris Cramer serves as the Vice President, Business Development of CytoSorbents Corporation. Chris started at CytoSorbents Corporation in April of 2013. Chris currently resides in the Greater New York City Area.